Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.